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Molecular angiogenesis 
Michael Klagsbrunl j2 and Marsha A Moses* 
New insights into the mechanisms by which blood vessels 
develop (angiogenesis) have been gained recently, primarily by 
the identification of factors that inhibit and promote this 
process. Angiogenesis-stimulating factors are being used to 
promote growth of new blood vessels in ischemic disease. In 
contrast, anti-angiogenesis factors are being used as inhibitors 
of neovascularization to control tumor growth and metastasis. 
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Introduction 
There is currently intense interest in delineating the 
mechanisms that regulate angiogenesis. This heightened 
scrutiny is due in part to the realization that aberrant 
angiogenesis contributes to pathology, for example, tumor 
growth and ocular retinopathies (reviewed in [ 11). Much of 
the basic research has been focused on detailing the steps 
involved in blood vessel growth and in identifying mol- 
ecules that can either enhance or inhibit angiogenesis. 
Promoters of angiogenesis have potential use in treatment 
of cardiac and limb ischemia (inadequate blood supply to 
an organ or body part; reviewed in [Z]). Inhibitors of angio- 
genesis have potential use as inhibitors of tumor growth 
and metastasis (reviewed in [3]). 
How does a blood vessel form? 
Blood vessel formation occurs through the processes of 
vasculogenesis and angiogenesis [46]. Vasculogenesis is 
the differentiation de ~OYO of vascular endothelial cells 
from precursor cells, known as angioblasts, during embry- 
onic development. This process is distinct from angiogen- 
esis, which is a remodeling process characterized by the 
sprouting of new blood vessels from pre-existing ones. 
Vasculogenesis was thought to occur only in early embryo- 
genesis. The existence of endothelial progenitor stem 
cells has been recently established, however, and these 
bone marrow-derived cells have been found to be incorpo- 
rated into neovascular foci in the adult, including injured 
corneas, ischemic hindlimbs and tumor vasculature, sug- 
gesting that vasculogenesis can occur in the adult [7-91. 
Angiogenesis occurs during embryogenesis and to a 
limited extent in the adult, for example in the female 
reproductive system, in physiological wound healing and 
in pathological disease processes such as cancer. 
The individual events that occur during angiogenesis are 
shown schematically in Figure 1. Angiogenesis is stimu- 
lated by factors such as vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF), which will be 
described at greater length below. An early response to 
angiogenesis-stimulating factors is the degradation of 
endothelial cell basement membrane by proteases, for 
example, by members of the matrix metalloproteinase 
(MMP) family. MMPs degrade collagen and other extra- 
cellular matrix components, disrupting the basement 
membrane barrier, enabling endothelial cells to migrate 
from pre-existing vessels towards angiogenic stimuli and to 
proliferate (reviewed in [lo]). Vascular cell-adhesion mol- 
ecules contribute to endothelial cell migration by mediat- 
ing cell-extracellular-matrix interactions. An important 
mediator is the integrin CQ&, a receptor for Arg-Gly-Asp 
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Processes in angiogenesis - the various 
steps in blood vessel formation. 
(a) Angiogenesis factors bind to their 
receptors on endothelial cells (EC) activating 
signal transduction pathways. (b) Matrix 
metalloproteinases (MMPs) are activated that 
degrade extracellular matrix allowing 
endothelial cells to migrate out of the 
pre-existing capillaty wall and to proliferate. 
(c) lntegrin cx$s is expressed by endothelial 
cells facilitating their adhesion to the 
extracellular matrix and their migration. 
(d) Angiopoietin-1 (Angl) binds to Tie-2 
receptors on endothelial cells. The result of 
this interaction is not clear at present but it 
has been suggested that Angl stimulates 
vessel sprouting, pericyte recruitment, and/or 
vessel survival and stabilization. 
(e) Endothelial cells release PDGF-BB, which 
is a chemoattractant for pericyte precursors. 
These ceils become associated with 
endothelial cells and differentiate into 
pericytes. Endothelial cells not covered by 
pericytes regress (not shown). 
(RGD)-containing proteins such as fibronectin, which is 
expressed at low levels in quiescent blood vessels 
(reviewed in [ll]). Integrin TV,,& expression is induced fol- 
lowing exposure to angiogenesis-stimulating factors, pref- 
erentially on the surface of endothelial cells in newly 
forming capillaries. Antagonists of CX& inhibit the growth 
of new blood vessels but not pre-existing ones, suggesting 
that cell adhesion is a critical step in angiogenesis [121. Fol- 
lowing migration and proliferation, endothelial cells assem- 
ble into tubes that have a patent lumen. Lumen formation 
may be dependent on E-selectin, a transmembrane cell- 
adhesion glycoprotein that mediates endothelial cell-cell 
contacts [13]. The nascent tubes form a primary vascular 
network. Following formation of small blood vessels, 
remodeling occurs to form larger mature vessels. An impor- 
tant step in producing a mature blood vessel is the recruit- 
ment of mesenchymal cells and their subsequent 
differentiation into smooth muscle cell-like pericytes that 
are thought to stabilize the newly forming vasculature. 
Pericytes are gradually attracted to a preformed endothelial 
plexus leading to progressive covering of the vascular tree 
[14]. During this period, regression of uncovered capillaries 
occurs, which ceases after acquisition of a pericyte coating. 
This later phase of blood vessel formation, therefore, is 
characterized by remodeling steps in which unprotected 
vessels are pruned and pericyte-covered vessels become 
stabilized and less prone to destabilization and regression. 
Platelet-derived growth factor (PDGF) plays a role in 
pericyte recruitment [15]. The PDGF-BB isoform is a 
potent chemoattractant and mitogen for pericytes and 
smooth muscle cells. PDGFB-deficient mouse embryos 
are characterized by a lack of pericyte association with 
blood vessels in some tissues. Furthermore, several 
microvascular beds are dilated and display microa- 
neurysms with hemorrhaging and edema occurring. 
These results suggest that PDGF-BB, probably from an 
endothelial cell source, recruits pericytes to associate 
with endothelial cells to increase blood vessel stability. 
Promoters of angiogenesis 
Vascular endothelial growth factor (VEGF) and its receptors 
VEGF plays a major role in regulating normal embryonic 
vasculogenesis and angiogenesis as well as tumor angio- 
genesis (reviewed in [16-191). VEGF is a 40-45 kDa 
homodimeric protein released by a number of cell types 
including most tumor cells. It is identical to vascular per- 
meability factor (VPF). VEGF monomers exist as five dif- 
ferent isoforms of 121, 145, 165, 189 and 206 amino acids 
that are produced by alternative splicing from a single 
gene containing eight exons. VEGFi2, and VEGF,,, are 
the most abundant isoforms. Although VEGF,,, is freely 
diffusable, VEGF,,, binds to heparan sulfate and becomes 
partially associated with cell surface and extracellular 
matrix heparan sulfate proteoglycan. Recently, other struc- 
turally homologous members of the VEGF family have 
been identified including placental growth factor (PLGF), 
VEGF-B, VEGF-C, VEGF-D and VEGF-E (reviewed in 
[19,20]). VEGF activities are mediated by high affinity 
receptor tyrosine kinases (RTKs) associated primarily with 
endothelial cells. Two VEGF RTKs have been identified, 
the 180 kDa fms-like tyrosine kinase (Flt-1) [Zl] and the 
200 kDa human kinase insert domain-containing receptor 
(KDR) and its murine homolog, Flk-1 [ZZ]. VEGF binds 
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to both Flt-1 and KDR/Flk-1 with high affinity but the 
VEGF signal that induces chemotaxis and mitogenicity is 
transduced preferentially via KDR/Flk-1 [23]. VEGF-C 
binds to a third structurally related RTK, the 180 kDa 
Flt4, which is preferentially expressed on lymphatic 
endothelium [24]. Recently, neuropilin-1, a neuronal cell 
receptor that mediates neuronal guidance, has been identi- 
fied as a receptor for VEGF as well [25]. Neuropilin-1 
binds VEGF,,, but not VEGFt2,. Neuropilin-1 differs 
from the other VEGF receptors in that it does not appear 
to be a tyrosine kinase receptor. In addition, it is expressed 
abundantly by nonendothelial cells, for example, tumor 
cells, thus allowing these cells to bind VEGF,,, in the 
absence of Flt-1 or KDR/Flk-1. Interestingly, other neu- 
ronal guidance molecules such as the ephrins have been 
recently reported to be angiogenic [26]. 
Targeted gene-disruption experiments have provided clues 
to the function of VEGF and its receptors. In each case, tar- 
geted disruption of VEGF of a receptor is embryonic lethal. 
Targeted disruption of even one allele of the VEGF gene 
results in impaired blood vessel formation and growth retar- 
dation suggesting tight dose-dependent regulation of 
embryonic vessel development by VEGF [27,28]. Targeted 
disruption of the KDR/Flk-1 gene in mice results in early 
defects in the differentiation and development of endothe- 
lial cells [29]. In these mice, yolk-sac blood vessels are 
absent and there are no organized blood vessels at any stage. 
In targeted disruption of Flt-1, normal endothelial cell dif- 
ferentiation from precursor cells occurs, but endothelial cell 
assembly into blood vessels is impaired [30]. Therefore, 
Flk-1 seems to function earlier than Flt-1. In mice targeted 
for disruption of Flt4, vasculogenesis and angiogenesis 
occur but large vessels become abnormally organized with 
defective lumens [31]. These results suggest a role for Flt4 
in embryonic vascularization before emergence of the lym- 
phatic system. Targeted disruption of neuropilin-1 results in 
embryonic death because of cardiovascular defects [32]. 
Although developmentally significant, VEGF-mediated 
angiogenesis is rare in the adult. One exception is the 
female reproductive system where it has been demon- 
strated that VEGF expression is correlated with vasculariza- 
tion of ovarian follicles, development of the corpus luteum, 
repair of endometrial vessels and angiogenesis at the site of 
embryo implantation [33]. VEGF-induced angiogenesis 
may also be involved in physiological wound healing and 
tissue repair. Use of VEGF for inducing collateral develop- 
ment in ischemic patients will be described below. 
VEGF is a prime contributor to tumor angiogenesis. Most 
tumor cells produce high levels of VEGF and VEGF 
receptors are associated with tumor endothelial cells. 
[18,34,35]. VEGF expression is induced by oncogenes 
such as Ras and inhibited by tumor suppressors such as 
von Hippel Landau (VHL) protein [36]. Inactivation of 
VHL results in overproduction of VEGF. VEGF expres- 
sion is upregulated by hypoxia and is often elevated in 
regions of tumor necrosis (reviewed in [37]). Hypoxia 
upregulates VEGF expression by activating a hypoxia- 
inducible factor-l (HIF-l)-binding sequence in the VEGF 
promoter, which results in increased VEGF mRNA tran- 
scription and stability. Taken together, these data provide 
evidence that VEGF is a tumor-derived paracrine angio- 
genesis factor whose expression results in the delivery of 
the 0, and nutrients needed for tumor growth. 
Angiopoietins and Tie receptors 
Tie receptors and their ligands, the angiopoietins, 
(reviewed in [38,39]) play a critical role in embryonic angio- 
genesis, but not vasculogenesis. Tie receptors, Tie1 and 
Tie2 (also known as Tek), are tyrosine kinases expressed 
by endothelial cells. Tie expression follows VEGF receptor 
expression and these receptors support functions of more 
mature endothelium, for example, vessel sprouting, 
branching and stabilization of vascular networks [40]. Mice 
deficient in Tie2 are embryonic lethal with defects in the 
proper development of the endothelial lining of the heart. 
The primary capillary plexus fails to remodel into small and 
large vessels [41,42]. Tie1 is required for the structural 
integrity of endothelial cells. Mice deficient in Tie1 die by 
birth due to edema and hemorrhaging [42]. 
Angiopoietin-1 (Angl) is a ligand for Tie2 [43]. A ligand 
for Tie1 has not yet been described. Angl (70 kDa) 
induces tryosine phosphorylation of Tie2 in endothelial 
cells but does not induce endothelial cell chemotaxis or 
proliferation. However, Angl has been shown to induce 
the formation of capillary sprouts and promote survival of 
endothelial cells [44]. Overexpression of Angl results in 
more numerous and more highly branched vessels [45]. 
Targeted disruption of Angl is embryonic lethal and the 
defects in these mice resemble those in the Tie-2 de& 
cient mice [45]. In addition to heart defects, there are a 
reduced number of vessels and remodeling of the initial 
primary capillary network does not occur. Importantly, 
there is a lack of recruitment of periendothelial supporting 
cells to the endothelial cells in Angl-deficient mice, which 
leads to lack of blood vessel stabilization and maturation. 
A mutation in the tyrosine kinase domain of Tie2 has 
been linked to venous malformation, a pathology in which 
veins have a deficient amount of smooth muscle cells [46]. 
Angl is expressed embryonically, most prominently in 
heart myocardium. Later in development, Angl is associ- 
ated with the mesenchyme surrounding developing 
vessels and in close association with endothelial cells [39]. 
It has been suggested that mesenchymal cells produce 
Angl, which activates Tie’2 on endothelial cells which in 
turn leads to the production and release of factors that 
recruit pericytes and smooth muscle cells, for example, 
PDGF-BB (reviewed in [4]). 
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Another member of the angiopoietin family has been 
described recently - angiopoietin-‘2 (Ang2) [47]. Ang’2 is 
60% identical to Angl but does not stimulate Tie2 tyrosine 
phophorylation. AngZ might be a natural antagonist of 
Angl that blocks Angl activation of Tie2 and angiogenesis. 
Targeted overexpression of Ang2 in blood vessels resulted 
in vascular defects that resemble those in mice deficient in 
Angl or Tie& presumably by inhibiting Angl function. 
Fibroblast growth factor (FGF) 
Acidic and basic fibroblast growth factor (FGF-1 and 
FGF-2, respectively), are very potent inducers of 
endothelial cell migration, proliferation and tube forma- 
tion in vitro and are highly angiogenic in &vo (reviewed in 
[48]). The FGFs were among the first angiogenic factors 
to be well characterized and there is a large body of litera- 
ture that describes FGF interactions with endothelial 
cells. Unlike VEGF and Angl, however, an important role 
for FGFs in the development of the embryonic vascula- 
ture has not been demonstrated. This may be because, in 
contrast to VEGF, FGF is not a specific endothelial cell 
growth factor but is pleiotropic, and has many cell targets 
including smooth muscle cells and neurons. Nevertheless, 
based on their potency in inducing angiogenesis in viva, 
FGFs are being used currently to stimulate collateral for- 
mation in ischemic limbs and hearts. 
Therapeutic angiogenesis 
Angiogenesis factors, such as FGF and VEGF, have the 
potential of augmenting collateral vessel development in 
myocardial and hindlimb ischemia (reviewed in [Z]). In 
animal models, recombinant FGF-2 augmented collateral 
vessels in the lower limb of rabbits with acute hind limb 
ischemia and increased collateral vessel formation in dogs 
with infarcted myocardium. VEGF,,, both recombinant 
protein and cDNA, augmented collateral vessel formation 
in ischemic limbs. Angiogenesis factors are now being used 
clinically as a treatment for ischemia. For example, follow- 
ing treatment with VEGF,,, cDNA, improved blood flow 
to the ischemic limb has been observed in patients with 
rest pain and improved myocardial perfusion has been 
observed in patients with severe myocardial ischemia. 
Inhibitors of angiogenesis 
A number of angiogenesis inhibitors have been described 
recently (Figure 2). For example, there are natural mol- 
ecules that apparently act directly on endothelial cells to 
block their migration, proliferation, and/or their ability to 
form capillary-like tubes. These include proteins such as 
angiostatin, endostatin, platelet factor-4, thrombospondin-1, 
interferon-a, tissue inhibitors of metalloproteineases, tro- 
ponin I and others (reviewed in [3]). Several low molecu- 
lar mass compounds that inhibit angiogenesis have been 
identified such as AGM 1470 [49] and thalidomide [SO]. 
There also has been an effort to design inhibitors that 
intervene at various steps in the process of blood vessel 
formation (Figure 2). Examples are antibodies directed 
against VEGF, soluble receptors that sequester ligands and 
prevent access to VEGF and Tie receptors, VEGF receptor 
tyrosine kinase inhibitors, and antagonists of MMPs and 
integrin o$&. Some of these angiogenesis inhibitors with 
potential clinical application will be described here. 
Thrombospondin-1 
A 140 kDa fragment of thrombospondin-1 (TSP-1) was 
one of the first natural angiogenesis inhibitors to be 
described ([Sl]; reviewed in [ 1,3]). TSP-1 is an inhibitor of 
tumor growth and metastases in a number of animal 
models. Its expression is inversely correlated with angio- 
genie activity. For example, TSP-1 is down-regulated 
during tumorigenesis while angiogenesis activity is ele- 
vated [Sl]. In subsequent studies of fibroblasts cultured 
from patients with Li-Fraumeni disease, it was shown that 
TSP-1 is regulated by thep53 tumor suppressor gene [Xl. 
Loss of $53 results in suppression of TSP-1 and a con- 
comitant increase in angiogenic activity. 
Angiostatin 
Angiostatin is a 38 kDa internal fragment of plasminogen 
that encompasses the first four kringle domains of plas- 
minogen [53]. It had been observed by clinicians that 
resection of certain primary tumors resulted in the rapid 
growth of previously dormant metastases. When a murine 
Lewis Lung carcinoma primary tumor was resected, 
distant lung metastases in these test mice grew signifi- 
cantly, in contrast to the control tumor-bearing mice, sug- 
gesting that the primary tumor produced an inhibitor of 
angiogenesis that suppressed growth of metastases, 
keeping them dormant. Angiostatin was purified from the 
serum and urine of these mice as an endothelial cell/angio- 
genesis inhibitor that blocked primary tumor growth and 
suppressed distant metastases in a variety of human 
tumors. Angiostatin enables micrometastases to remain 
dormant by increasing the tumor cell apoptotic rate. 
Whereas the rates of tumor cell proliferation in growing 
and dormant metastases were equivalent, the apoptotic 
rates in tumor cells were threefold higher in the dormant 
metastases [54]. Thus, tumor dormancy might be 
explained by a balance in tumor cell growth and death in 
the presence of angiogenesis promoters and suppressors. 
Tumor cells do not synthesize angiostatin directly, but 
may instead produce and secrete an as yet an unidentified 
enzyme that enters the circulation and interacts with plas- 
minogen to release the angiostatin portion. 
A recent report demonstrated that the ATP synthase F, 
complex is an angiostatin-binding protein [SS]. This ATP 
synthase had previously been localized intracellularly to 
the mitochondria. It was speculated that when this 
enzyme is present on the surface of endothelial cells it 
may produce ATP which upon diffusion into the cell 
serves as an additional ATP source for endothelial cells. It 
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Figure 2 
Processes in angiogenesis that are vulnerable 
to antagonists. (a) VEGF antagonists. VEGF 
is neutralized by specific anti-VEGF 
antibodies and sequestered by soluble 
receptors. Specific inhibitors of VEGF 
receptor tyrosine kinases inhibit 
VEGF-mediated signal transduction. 
(b) Antagonists of extracellular matrix (ECM) 
degradation, endothelial cell adhesion and 
migration. MMP inhibitors suppress enzyme 
activity preventing degradation of extracellular 
matrix and subsequent endothelial cell 
migration. Antibodies directed against integrin 
oJ3s and cyclic RGD peptides block integrin 
a& function, thereby inhibiting endothelial 
cell adhesion to extracellular matrix and 
migration. (c) Natural antagonists interact with 
endothelial cells to block endothelial cell 
migration, proliferation and/or tube formation, 
thereby inhibiting tumor growth and 
metastasis. These antagonists include 
angiostatin, endostatin, thrombospondin-1 
and troponin I. Metastasis, which requires 
tumor cell exit from blood vessels, can also be 
blocked by MMP inhibitors. 
(a) VEGF antagonists 
VEGFR tyrosine 
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neutralization 
anti-MMPs 
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may be that angiostatin interferes with ATP production 
resulting in endothelial cell growth inhibition. 
Endostatin 
Endostatin is a 20 kDa carboxy-terminal fragment of colla- 
gen XVIII, purified from the conditioned media of 
hemangioendothelioma cells [56]. Like angiostatin, endo- 
statin is a cryptic angiogenesis inhibitor released from a 
larger parent molecule that itself is not anti-angiogenic [3]. 
The identity of the enzyme that releases endostatin from 
collagen XVIII is unknown. Endostatin specifically 
inhibits capillary endothelial cell proliferation in a&u and 
is a potent inhibitor of the growth of primary and metasta- 
tic tumors [56-581. Endostatin has several properties that 
suggest it might be of potential clinical use as an anti- 
angiogenic agent. One is that endostatin does not induce 
drug resistance as do conventional chemotherapy and radi- 
ation. In addition, in mouse tumor models, repeated cycles 
of administering and withdrawing systemic endostatin 
results in prolonged tumor dormancy without further 
treatment, suggesting that endostatin could completely 
suppress a tumor rather than just inhibit it transiently [59]. 
Troponin 
Troponin I (TnI) is a recently described 22 kDa angio- 
genesis inhibitor isolated from cartilage [60]. Its discov- 
ery in cartilage as an anti-angiogenesis factor was 
ub ected because this protein is considered to be a 
muscle tissue-specific inhibitor of actomyosin ATPase, 
whose function is the Ca+z-dependent regulation of 
muscle contraction as part of the troponin complex. TnI 
is an endothelial cell-specific inhibitor of FGF- and 
VEGF-driven capillary endothelial cell proliferation in 
vitro and of neovascularization in chorioallantoic mem- 
brane (CAM) and cornea models. TnI delivered systemi- 
cally significantly inhibited lung metastases of murine 
B16-BL6 melanoma, a very aggressive variant of B16- 
FlO melanoma. Interestingly, TnI is used clinically as a 
sensitive serum marker to assess the degree of myocar- 
dial damage during infarction. It is speculated that the 
anti-angiogenic properties of TnI might be responsible 
for the difficulty in revascularizing ischemic myocardium 
following injury. 
Inhibitors of VEGF, VEGF and Tie receptors 
Several strategies have been developed to block VEGF 
action. For example, anti-VEGF antibodies decreased the 
vessel density and growth rate of several human tumors in 
nude mice but did not inhibit tumor cell growth in vitro 
[61]. More recently, humanized anti-VEGF monoclonal 
antibodies have been developed for clinical application 
that inhibit VEGF-induced endothelial cell proliferation 
and tumor growth [62]. Anti-VEGF antibodies have also 
been used to suppress iris neovascularization associated 
with retinal ischemia in nonhuman primates [63]. 
Soluble VEGF and Tie receptors have been explored as 
angiogenesis inhibitors with the rationale that they might 
sequester angiogenic ligands. A natural soluble Flt-1 
receptor (sFLT-l), produced by endothelial and tumor 
cells has been identified as an alternative splice product 
that contains the first six of the seven amino-terminal 
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immunoglobulin-like domains of Flt-1 [64]. Soluble 
Flt-1 binds VEGF with high affinity and forms a hetero- 
dimeric complex with KDR. sFLT-1 protein inhibits 
VEGF-induced endothelial cell proliferation. Transfec- 
tion of tumor cells with sFLT-1 resulted in reduced 
tumor growth and metastasis [65]. These results suggest 
that sFLT-1 acts as an angiogenesis inhibitor by seques- 
tering VEGF and/or by acting as a dominant negative 
effector by forming heterodimers with transmembrane 
VEGFR tyrosine kinases. Soluble Flt-1 and Flk-1 recep- 
tors have been demonstrated to suppress retinal neovas- 
cularization in a murine model of ischemic retinopathy 
[66]. A similar experimental strategy has been used for 
Tie receptors. A soluble recombinant extracellular domain 
of Tie2 (ExTek.bHis) substantially inhibited angiogenesis, 
tumor growth and metastases [67]. 
Another approach to inhibiting angiogenesis has been to 
inactivate receptors by inhibiting tyrosine kinase activity. 
SU5416 is a small synthetic compound that is a selective 
inhibitor of Flt-l/KDR tyrosine kinase. It inhibits VEGF- 
induced endothelial cell proliferation but not tumor-cell 
growth in vitro [68]. It also inhibits angiogenesis-depen- 
dent tumor growth and is now being evaluated in Phase I 
clinical trials. 
Metalloproteinase inhibitors 
The proteolytic degradation and remodeling of the extra- 
cellular matrix by migrating and proliferating capillary 
endothelial cells is one of the earliest and sustained events 
in angiogenesis. This process is mediated by MMPs and 
by serine proteases. Inhibition of MMPs is a potential 
therapeutic intervention site for anti-angiogenic therapies., 
An endogenous tissue inhibitor of metalloproteinases’ 
(TIMP) derived from cartilage was first shown to inhibit 
both embryonic and tumor-induced angiogenesis in oivo 
[69]. Subsequently, TIMP-1, TIMP-2 and TIMP-3 have 
been shown to have various anti-angiogenic activities 
(reviewed in [lo]). These studies have led to the develop- 
ment of a number of synthetic metalloproteinase 
inhibitors, which are currently being tested in clinical 
trials against a variety of cancers including ovarian, lung 
and breast cancers. 
Antagonists of a& 
Integrin a& expression is upregulated in endothelial 
cells as a response to endothelial cell growth factors such 
as FGF-‘2 and VEGF suggesting that it modulates 
endothelial cell migration and proliferation [ 121. Disrup- 
tion of integrin a& with anti-a,& antibody or cyclic 
peptide antagonists of a&, prevents new, but not pre- 
existing, blood vessel formation in angiogenesis model 
systems, in transplanted human skin and in tumors [ll]. 
These aJ13 antagonists are currently in clinical trials as a 
treatment for cancer. Interestingly, proteolytic and cell 
adhesion events may be linked in the regulation of 
angiogenesis. Integrin a& binds directly to MMP-2 on 
the surface of invading endothelial cells thereby facilitat- 
ing the cell-surface localization of this enzyme as well as 
potentiating its cell-mediated extracellular matrix degra- 
dation. During angiogenesis, however, a noncatalytic 
carboxy-terminal hemopexin-like domain of MMP-2 
(known as PEX) is generated that blocks integrin-MMP- 
2 interactions, resulting in suppression of collagenolytic 
activity and the inhibition of angiogenesis and tumor 
growth [70]. These events may constitute a feedback 
system that eventually down-regulates angiogenesis after 
the initial stimulus. 
Conclusions and prospects 
Interest in angiogenesis has grown dramatically in recent 
years for several reasons. One is the identification of 
angiogenesis factors such as VEGF, angiopoietin and their 
receptors, factors that play a key role in regulating angio- 
genesis. A series of targeted gene ‘knockout’ studies in 
mice and other approaches have begun to elucidate the 
mechanisms by which these molecules contribute to the 
vasculogenic and angiogenic processes during develop- 
ment. Secondly, a strong clinical interest has emerged in 
developing anti-angiogenesis reagents as therapeutic 
strategies for inhibiting tumor growth and metastasis, as 
well as a variety of ocular pathologies. Angiogenesis factors 
such as VEGF and FGF also have clinical utility in pro- 
moting therapeutic angiogenesis in ischemic disease. It is 
anticipated that the mechanisms by which angiogenic 
modulators exert their effects will become better under- 
stood and that a new generation of potent drugs capable of 
promoting or inhibiting angiogenesis will be developed. 
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